Dynavax Announces Receipt of Communication from the U.S. FDA on HEPLISAVTM Hepatitis B Vaccine

Dynavax Technologies Corporation announced receipt of communication from the U.S. Food and Drug Administration (FDA) regarding the clinical hold on the two HEPLISAVTM Investigational New Drug (IND) Applications, for healthy adults and patients with end-stage renal disease (ESRD)

BERKELEY, CA, USA | February 09, 2009 | Dynavax Technologies Corporation (Nasdaq: DVAX) today announced receipt of communication from the U.S. Food and Drug Administration (FDA) regarding the clinical hold on the two HEPLISAVTM Investigational New Drug (IND) Applications, for healthy adults and patients with end-stage renal disease (ESRD). In this communication, the FDA has requested additional clinical and safety information which the agency indicated may be helpful in its risk assessment of the two INDs and may assist in finding a development path forward for HEPLISAV hepatitis B vaccine, not only in ESRD patients but also in healthy adults.

This communication followed a Clinical Hold Oversight Meeting held at the FDA on January 8, 2009. Dynavax believes the information requested by the FDA is available and intends to provide this to the agency in the near future.

Since March 2008, the two INDs for HEPLISAV have been and remain on clinical hold by the FDA in the United States.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops a diversified, well-funded pipeline of novel Toll-like Receptor (TLR) product candidates. Based on Dynavax's proprietary technology platforms, these products specifically modify the innate immune response to infectious, respiratory, autoimmune, and inflammatory diseases. Dynavax's product programs are supported by global partnerships with leading pharmaceutical companies such as GlaxoSmithKline, AstraZeneca AB, and Novartis as well as funding from Symphony Dynamo, Inc. and the National Institutes of Health. For more information visit www.dynavax.com.

SOURCE: Dynavax Technologies Corporation

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top